Affiliation: University of North Carolina
- Increased risk of rectal cancer after prostate radiation: a population-based studyNancy N Baxter
Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Gastroenterology 128:819-24. 2005..Radiation therapy for prostate cancer has been associated with an increased rate of pelvic malignancies, particularly bladder cancer. The association between radiation therapy and colorectal cancer has not been established...
- Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapyJanine M Davies
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
Radiat Oncol 6:114. 2011..Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC...
- Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapyBERT H O'NEIL
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
Oncologist 12:1425-32. 2007..This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease...
- Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)BERT H O'NEIL
UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
Semin Oncol 32:35-42. 2005..Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article...
- Current options for the management of rectal cancerBERT H O'NEIL
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
Curr Treat Options Oncol 8:331-8. 2007....
- High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyBERT H O'NEIL
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
J Clin Oncol 25:3644-8. 2007....
- Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trialsBERT H O'NEIL
Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
Oncologist 13:1074-83. 2008..Recent innovations in chemotherapy for mCRC are reviewed, with a focus on emerging data that may significantly improve both survival and quality of life for patients with CRC in the future...
- Gemcitabine radiosensitization for rectal cancer: step forward or dance step?BERT H O'NEIL
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Cancer J 11:110-2. 2005
- Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment optionsJanine Marie Davies
University of North Carolina, Division of Hematology Oncology, 170 Manning Dr, CB 7305, Chapel Hill, NC 27599, USA
Expert Opin Investig Drugs 18:913-9. 2009....
- Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinomaBERT H O'NEIL
University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599 730, USA
J Clin Oncol 29:2350-6. 2011..CONCLUSION In this study of selumetinib for patients with HCC, no radiographic responses were seen and time to progression was short, which suggests minimal single-agent activity despite evidence of suppression of target activation...
- Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomasBERT H O'NEIL
Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Oncology 72:97-104. 2007..Recent information has implicated IkappaB family members (e.g. Bcl-3) as possible mediators of NF-kappaB activation. Therefore, we examined the expression of all NF-kappaB family members and downstream targets in HCC...
- Phase I trial of vinflunine and pemetrexed in refractory solid tumorsHanna K Sanoff
Department of Medicine, Division of Hematology Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Invest New Drugs 29:131-6. 2011..Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients with refractory solid tumors...
- Antiangiogenic therapies for advanced hepatocellular carcinomaKeeran R Sampat
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Oncologist 18:430-8. 2013..Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed...
- The proteasome as a target for cancer therapyPeter M Voorhees
The Lineberger Comprehensive Cancer Center, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7295, USA
Clin Cancer Res 9:6316-25. 2003..Below we discuss the rationale behind targeting the proteasome for cancer therapy, and review the preclinical and clinical data on proteasome inhibitors alone, and in combination with conventional chemotherapeutics...
- Targeted therapies for hepatocellular carcinomaMatthew R Skelton
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Clin Adv Hematol Oncol 6:209-18. 2008..Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs...
- A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or HigherUsman Shah
Division of Medical Oncology, University of North Carolina, Chapel Hill, NC
Gastrointest Cancer Res 3:45-8. 2009....
- Targeted therapy in colorectal cancerSupriya Rajpal
University of California, San Francisco, Division of Hematology Oncology, 505 Parnassus Avenue, Box 1270, San Francisco, CA 94143 1270, USA
Clin Adv Hematol Oncol 4:124-32. 2006..Further advances in the treatment of CRC are expected through continued scientific investigation and well-designed clinical trials...
- Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinomaAlan P Venook
Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
Cancer 103:2435-46. 2005..Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma...
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg
Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
Ann Oncol 19:946-50. 2008..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
- Cetuximab in the treatment of colorectal cancerRichard M Goldberg
Division of Hematology Oncology, University of North Carolina, Chapell Hill, NC, USA
Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancerAndrew H Ko
Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
Int J Radiat Oncol Biol Phys 68:809-16. 2007..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
- Rectal cancer radiotherapyShelileah Ramsey
Department of Radiation Oncology, University of North Carolina School of Medicine, UNC Lineberger Clinical Cancer Center, Chapel Hill, NC 27599 7512, USA
Cancer J 13:204-9. 2007....
- Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomasAbigail S Caudle
Department of Surgery, Division of Surgical Oncology, University of North Carolina School of Medicine, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599, USA
Ann Surg Oncol 14:577-82. 2007..Preoperative RT offers theoretical advantages in the multidisciplinary care of RPS. The purpose of our study was to evaluate our experience using preoperative radiotherapy (PRT) in the treatment of RPS...
- Cancer and leukemia group B gastrointestinal cancer committeeRichard M Goldberg
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Clin Cancer Res 12:3589s-95s. 2006..Future efforts aim to evolve new standards of care, evaluate new therapies, and answer relevant biological questions in gastrointestinal cancer...
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 StudyJeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
- Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901David P Ryan
Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
J Clin Oncol 24:2557-62. 2006..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma...
- Dose optimization via index-dose gradient minimizationSha X Chang
Department of Radiation Oncology, University of North Carolina at Chapel Hill, 27599 7512, USA
Med Phys 29:1130-46. 2002..The primary advantages of our optimization algorithm include computational efficiency, intensity modulation selection choice, and performance reliability for a wide range of clinical beam setups and optimization objectives...
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
Int J Radiat Oncol Biol Phys 54:386-96. 2002..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
- Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114Jeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:648-57. 2004..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
J Clin Oncol 22:1785-96. 2004..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
- Patient selection, realism, and randomized clinical trialsJoel E Tepper
J Clin Oncol 22:3215-7. 2004
- Staging of colorectal cancer: past, present, and futureJanet K Horton
Department of Radiation Oncology, University of North Carolina, Chapel Hill 27599, USA
Clin Colorectal Cancer 4:302-12. 2005..Staging in the future is likely to be a complicated combination of anatomic and biologic markers used together in mathematic modeling to group patients into prognostic risk groups, which can be used to guide tailored therapy...
- Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysisNancy N Baxter
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Int J Radiat Oncol Biol Phys 61:426-31. 2005..To determine the impact of preoperative radiotherapy (RT) on the accuracy of lymph node staging (LNS). Preoperative RT is a well-established component of rectal cancer treatment but its impact on LNS is unknown...
- An embarrassment of riches: neoadjuvant therapy of rectal cancerJoel E Tepper
J Clin Oncol 23:1339-41. 2005
- In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancerKaryn B Stitzenberg
Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
Ann Surg Oncol 14:1515-6. 2007..We are investigating the feasibility of partial breast irradiation using a single fraction of IORT delivered to the tumor in vivo prior to surgical resection...
- Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiativeDavid E Morris
Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
Int J Radiat Oncol Biol Phys 62:3-19. 2005....
- Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancerJoel E Tepper
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Semin Radiat Oncol 12:187-95. 2002..These should be used as guides for defining appropriate field arrangements for the adjuvant postoperative therapy of gastric cancer...
- Rectal cancer: can we throw away the scalpel?Michael O Meyers
Ann Surg Oncol 12:95-7. 2005
- ASTRO 45th annual meeting presidential address: Medicine's arrow, medicine's cycle: lessons for radiation oncologyJoel E Tepper
Int J Radiat Oncol Biol Phys 59:623-33. 2004
- Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreasA William Blackstock
Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC 277516, USA
Int J Gastrointest Cancer 34:107-16. 2003..Determine the safety and efficacy of twice weekly gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with surgically staged, locally advanced pancreatic cancer...
- Risk of pelvic fractures in older women following pelvic irradiationNancy N Baxter
Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis 55455, USA
JAMA 294:2587-93. 2005..Pelvic fractures, including hip fractures, are a major source of morbidity and mortality in older women. Although therapeutic pelvic irradiation could increase the risk of such fractures, this effect has not been studied...
- Is less more? Lessons in radiation schedules in breast cancerCarolyn I Sartor
J Natl Cancer Inst 94:1114-5. 2002
- Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgeryNancy N Baxter
Department of Surgery, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Ann Surg 245:553-9. 2007..To determine the risk of small bowel obstruction (SBO) after irradiation (RT) for rectal cancer..